Stock analysts at Berenberg Bank assumed coverage on shares of Oncimmune (LON:ONC) in a report issued on Friday. The firm set a “buy” rating and a GBX 169 ($2.29) price target on the stock. Berenberg Bank’s price objective points to a potential upside of 26.12% from the company’s previous close.
Shares of Oncimmune (ONC) traded up GBX 6.50 ($0.09) during trading hours on Friday, hitting GBX 134 ($1.82). Oncimmune has a 1 year low of GBX 100 ($1.36) and a 1 year high of GBX 150 ($2.03). The stock has a market capitalization of $72.57 and a PE ratio of -1,340.00.
COPYRIGHT VIOLATION WARNING: “Oncimmune (ONC) Receives New Coverage from Analysts at Berenberg Bank” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/21/oncimmune-onc-receives-new-coverage-from-analysts-at-berenberg-bank.html.
Oncimmune Company Profile
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.
Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.